A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.

Date publication

août 2016

Journal

Clinical chemistry

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Pr BIBEAU Frédéric

Tous les auteurs :
Garrigou S, Perkins G, Garlan F, Normand C, Didelot A, Le Corre D, Peyvandi S, Mulot C, Niarra R, Aucouturier P, Chatellier G, Nizard P, Perez-Toralla K, Zonta E, Charpy C, Pujals A, Barau C, Bouché O, Emile JF, Pezet D, Bibeau F, Hutchison JB, Link DR, Zaanan A, Laurent-Puig P, Sobhani I, Taly V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27251038

Résumé

Circulating tumor DNA (ctDNA) has emerged as a good candidate for tracking tumor dynamics in different cancer types, potentially avoiding repeated tumor biopsies. Many different genes can be mutated within a tumor, complicating procedures for tumor monitoring, even with highly sensitive next-generation sequencing (NGS) strategies. Droplet-based digital PCR (dPCR) is a highly sensitive and quantitative procedure, allowing detection of very low amounts of circulating tumor genetic material, but can be limited in the total number of target loci monitored.

Mots clés

Adaptor Proteins, Signal Transducing, genetics, Aged, Biomarkers, Tumor, genetics, Colorectal Neoplasms, genetics, DNA Methylation, genetics, DNA, Neoplasm, blood, Female, Humans, Male, Neuropeptide Y, genetics, Polymerase Chain Reaction, Repressor Proteins, genetics

Référence

Clin. Chem.. 2016 Aug;62(8):1129-39